High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study

Abstract

Alemtuzumab was able to control the disease course in patients who stopped natalizumab; of course, as this is a single-centre study and the number of patients is small, these findings are very preliminary and need further confirmation.